Target intelligence / Profile preview

Vibrio cholerae O1 Inaba lipopolysaccharide (V. cholerae O1 Inaba LPS)

Target
V. cholerae O1 Inaba LPS
Molecular classification
Lipopolysaccharide, Bacterial surface antigen, Glycolipid
01

Overview

Vibrio cholerae O1 Inaba lipopolysaccharide (LPS) is a critical surface-exposed glycolipid of the Gram-negative bacterium Vibrio cholerae, the causative agent of cholera (Chatterjee & Chaudhuri, 2011). The LPS molecule is composed of three regions: the hydrophobic lipid A, a core oligosaccharide, and the O-specific polysaccharide (O-antigen) (Kenne et al., 1982). The O-antigen of the Inaba serotype is characterized by a homopolymer of alpha(1-2)-linked 4-amino-4,6-dideoxy-D-mannose (perosamine) units that specifically lack the 2-O-methyl group found in the Ogawa serotype (Ito et al., 1993). This O-antigen is the primary target for protective immunity, as antibodies directed against it can prevent bacterial attachment to the intestinal mucosa and promote vibriocidal activity (Clemens et al., 2017). Consequently, Inaba LPS is a key component in both killed and live-attenuated oral cholera vaccines, such as Dukoral and Shanchol (WHO, 2017). Therapeutic strategies focusing on this target primarily involve immunization to elicit long-lasting mucosal and systemic antibody responses to prevent the severe dehydration and diarrhea associated with cholera outbreaks (Harris et al., 2012). Additionally, the LPS serves as a diagnostic marker for identifying the Inaba serotype during epidemiological surveillance (CDC, 2022). The structural integrity of the LPS is also essential for the bacterium's resistance to bile salts and other environmental stressors within the host's small intestine (Chatterjee & Chaudhuri, 2011). Research into synthetic O-antigen conjugates continues to explore more stable and immunogenic alternatives to traditional whole-cell vaccines (Grandjean et al., 2014).

Other names
Inaba O-antigenVibrio cholerae O1 Inaba O-specific polysaccharideO1 Inaba LPSV. cholerae O1 Inaba surface antigen
02

Mechanism of action

Induction of protective mucosal immunity (IgA) and serum vibriocidal antibodies that inhibit bacterial colonization and neutralize the pathogen (WHO, 2017; Clemens et al., 2017).

03

Biological functions

Bacterial cell wall integrityPathogenesisImmune evasionEndotoxicity
04

Disease associations

CholeraInfection
05

Safety considerations

EndotoxicityReactogenicitySerotype switching (Inaba to Ogawa)Cross-reactivity issues
06

Interacting drugs

Dukoral

5 more in the full profile.

07

Biomarkers

Vibriocidal antibody titerAnti-Inaba O-antigen IgAAnti-Inaba O-antigen IgG

Beyond the preview

Go deeper on Vibrio cholerae O1 Inaba lipopolysaccharide (V. cholerae O1 Inaba LPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibrio cholerae O1 Inaba lipopolysaccharide (V. cholerae O1 Inaba LPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call